All In Biotech

Drug Trial Radar · NCT04898751

Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors

Last checked: Nov 20, 2026Latest source record: May 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

2,214

Actual

Start

Jan 1, 2008

Primary completion

Aug 31, 2020

Study completion Aug 31, 2020

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 24, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Immune checkpoint inhibitors (ICIs) are associated with a wide variety of cutaneous immune-related adverse events (cirAEs). These cirAEs are reported to be the most common immune-related adverse events (irAEs) and the first to appear. This study examines the appearance of cirAEs within the World Health Organization (WHO) pharmacovigilance database, VigiBase.

Conditions

  • Cutaneous Toxicity From ICI Therapy

Interventions

  • Immune checkpoint inhibitor (ICI)Drug

    Immune checkpoint inhibitors included were targeting either PD-1, PD-L1 or CTLA-4, and had received FDA approval at the time of study (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32), and Cemiplimab (L01XC33).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cutaneous toxicity of ICIsTime frame: From 01/01/2008 to 08/31/2020

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sidney Kimmel Comprehensive Care Center

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.